Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CFO Sells 5,295 Shares of Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CFO Maximo F. Nougues sold 5,295 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total value of $17,314.65. Following the completion of the sale, the chief financial officer now directly owns 166,678 shares of the company’s stock, valued at $545,037.06. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI traded down $0.18 on Tuesday, hitting $3.10. The company’s stock had a trading volume of 852,851 shares, compared to its average volume of 542,683. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.46 and a quick ratio of 1.38. The stock has a 50 day moving average of $3.99 and a 200-day moving average of $4.80. Puma Biotechnology, Inc. has a 12-month low of $2.13 and a 12-month high of $7.73. The company has a market capitalization of $149.54 million, a price-to-earnings ratio of 9.39 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.12. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. The firm had revenue of $43.80 million for the quarter, compared to analyst estimates of $41.53 million. As a group, research analysts predict that Puma Biotechnology, Inc. will post 0.22 EPS for the current year.

Hedge Funds Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Puma Biotechnology in the 1st quarter valued at $57,000. Ritholtz Wealth Management purchased a new stake in Puma Biotechnology in the 4th quarter valued at about $66,000. Crestline Management LP lifted its holdings in shares of Puma Biotechnology by 6.5% during the 4th quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 2,135 shares during the period. Jump Financial LLC boosted its position in shares of Puma Biotechnology by 131.7% in the fourth quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 32,510 shares during the last quarter. Finally, Citigroup Inc. purchased a new stake in Puma Biotechnology in the third quarter valued at approximately $262,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. StockNews.com upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, June 12th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Monday, June 3rd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.